Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Lymphoma 1Histiocytic Sarcoma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 88fludarabine phosphate 77Busulfan 56Tacrolimus 54Mycophenolic Acid 54Antilymphocyte Serum 48Peripheral Blood Stem Cell Transplantation 46Filgrastim 42Melphalan 41Cyclosporine 39Whole-Body Irradiation 38fludarabine 36Radiotherapy 32Methotrexate 28Cord Blood Stem Cell Transplantation 25Methylprednisolone 24Alemtuzumab 17Etoposide 16Thiotepa 15Rituximab 14Cytarabine 14thymoglobulin 13Granulocyte Colony-Stimulating Factor 12Stem Cell Transplantation 10sargramostim 9Sirolimus 9Flow Cytometry 9Psychiatric Rehabilitation 8Prednisone 7Mesna 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × selpercatinib × Myeloid × Clear all
NCT04320888 2026-05-27

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1 enrolled 3 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡